% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Gerhuser:142034,
author = {C. Gerhäuser$^*$ and F. Favero$^*$ and T. Risch and R.
Simon and L. Feuerbach$^*$ and Y. Assenov$^*$ and D.
Heckmann$^*$ and N. Sidiropoulos and S. M. Waszak and D.
Hübschmann and A. Urbanucci and E. G. Girma and V.
Kuryshev$^*$ and L. J. Klimczak and N. Saini and A. M.
Stütz and D. Weichenhan$^*$ and L.-M. Böttcher and R.
Toth$^*$ and J. D. Hendriksen and C. Koop and P. Lutsik$^*$
and S. Matzk and H.-J. Warnatz and V. Amstislavskiy and C.
Feuerstein$^*$ and B. Raeder and O. Bogatyrova$^*$ and E.-M.
Schmitz and C. Hube-Magg and M. Kluth and H. Huland and M.
Graefen and C. Lawerenz$^*$ and G. H. Henry and T. N.
Yamaguchi and A. Malewska and J. Meiners and D.
Schilling$^*$ and E.-M. Reisinger$^*$ and R. Eils$^*$ and M.
Schlesner$^*$ and D. W. Strand and R. G. Bristow and P. C.
Boutros and C. von Kalle$^*$ and D. Gordenin and H.
Sültmann$^*$ and B. Brors$^*$ and G. Sauter and C.
Plass$^*$ and M.-L. Yaspo and J. O. Korbel$^*$ and T.
Schlomm and J. Weischenfeldt},
title = {{M}olecular {E}volution of {E}arly-{O}nset {P}rostate
{C}ancer {I}dentifies {M}olecular {R}isk {M}arkers and
{C}linical {T}rajectories.},
journal = {Cancer cell},
volume = {34},
number = {6},
issn = {1535-6108},
address = {New York, NY},
publisher = {Elsevier},
reportid = {DKFZ-2018-02264},
pages = {996 - 1011.e8},
year = {2018},
abstract = {Identifying the earliest somatic changes in prostate cancer
can give important insights into tumor evolution and aids in
stratifying high- from low-risk disease. We integrated whole
genome, transcriptome and methylome analysis of early-onset
prostate cancers (diagnosis ≤55 years). Characterization
across 292 prostate cancer genomes revealed age-related
genomic alterations and a clock-like enzymatic-driven
mutational process contributing to the earliest mutations in
prostate cancer patients. Our integrative analysis
identified four molecular subgroups, including a
particularly aggressive subgroup with recurrent duplications
associated with increased expression of ESRP1, which we
validate in 12,000 tissue microarray tumors. Finally, we
combined the patterns of molecular co-occurrence and
risk-based subgroup information to deconvolve the molecular
and clinical trajectories of prostate cancer from single
patient samples.},
cin = {C010 / G200 / B063 / L101 / B080 / B240},
ddc = {610},
cid = {I:(DE-He78)C010-20160331 / I:(DE-He78)G200-20160331 /
I:(DE-He78)B063-20160331 / I:(DE-He78)L101-20160331 /
I:(DE-He78)B080-20160331 / I:(DE-He78)B240-20160331},
pnm = {313 - Cancer risk factors and prevention (POF3-313)},
pid = {G:(DE-HGF)POF3-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:30537516},
doi = {10.1016/j.ccell.2018.10.016},
url = {https://inrepo02.dkfz.de/record/142034},
}